PROCA1: A Protein Target for Drug Development (G147011)

Target Name: PROCA1

NCBI ID: G147011

PROCA1

PROCA1: A Protein Target for Drug Development

PROCA1, also known as Protein PROCA1 (isoform e), is a protein that is expressed in various tissues throughout the body. It is a key regulator of cell adhesion, meaning it helps keep cells together to form tissues and organs. PROCA1 is also involved in the formation of new blood vessels, and has been linked to the development and progression of certain diseases.

As a drug target, PROCA1 is an attractive target for researchers because of its unique structure and its involvement in several important cellular processes. PROCA1 is a transmembrane protein, which means it spans the cell membrane and is involved in the function of the cell as a whole. This makes it an attractive target for drugs that want to affect the entire cell, rather than just a specific protein.

One of the key challenges in studying PROCA1 is its high stability. PROCA1 is expressed in many different tissues and cells, and its levels can remain stable even after prolonged exposure to certain treatments. This makes it difficult to study the protein in its natural environment and to understand how it functions. However, researchers have been able to use various techniques, such as immunization and cell-based assays, to study its behavior in different contexts.

PROCA1 is also involved in several important cellular processes that are relevant to its function as a drug target. For example, PROCA1 is involved in the formation of new blood vessels, which can be a source of cancer cells. Researchers have found that PROCA1 is expressed in a variety of tissues that are cancer-prone, including the lungs, colon, and skin. This suggests that PROCA1 may be a useful biomarker for cancer diagnosis and treatment.

Additionally, PROCA1 is involved in the regulation of cell adhesion, which is a critical process that helps keep cells together to form tissues and organs. This is important for the development and maintenance of tissues and organs, and is also important for the development of cancer. Researchers have found that PROCA1 is involved in the regulation of cell adhesion in a variety of tissues, including the placenta, which plays a critical role in the development and maintenance of fetal tissues.

Another potential mechanism by which PROCA1 may be a drug target is its role in the development and progression of certain diseases. For example, PROCA1 has been linked to the development and progression of Alzheimer's disease, which is a condition characterized by the progressive loss of brain cells. Researchers have found that PROCA1 is expressed in the brains of people with Alzheimer's disease, and that its levels are reduced in the brains of people who have the condition. This suggests that PROCA1 may be a useful target for drugs that are designed to treat Alzheimer's disease.

In conclusion, PROCA1 is a protein that is expressed in various tissues throughout the body and is involved in several important cellular processes. Its stability and its involvement in the development and progression of certain diseases make it an attractive target for drug research. Further studies are needed to fully understand the role of PROCA1 in these processes and to develop effective treatments.

Protein Name: Protein Interacting With Cyclin A1

The "PROCA1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about PROCA1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets